How it was built
- The approach
Every load-bearing claim comes from a named guideline, trial, or meta-analysis, with the evidence dots (●●●●● = strong and replicated, down to ○○○○○ = essentially unproven) reflecting study design, size, and replication. Figures are group averages; individuals vary widely. This is educational, not a diagnosis or a prescription — and where the mainstream and functional camps genuinely disagree (T3/NDT, antibody-tracking, the 'optimal' TSH), it shows both sides rather than picking one.
- The key sources
What it is & why it hides: the StatPearls Hashimoto's review and ATA patient materials, plus the pre-clinical-antibody, hashitoxicosis, iodine-excess, and smoking-paradox literature. Tests & interpretation: the ATA thyroid-function-test guidance, the anti-TPO performance and Whickham-progression data, and the TSH reference-range debate. Treatment: the 2014 ATA hypothyroidism guideline, the 2021 ATA/BTA/ETA combination-therapy consensus, the TRUST trial (subclinical), and the 2017 ATA pregnancy guideline. Diet & supplements: the Teng iodine study (NEJM) and the U-shaped-curve data, the Krysiak gluten-free pilot, the Abbott AIP study, the selenium meta-analyses, and the Farhangi Nigella sativa trial. The frontier: the LDN autoimmune literature, the peptide reviews, the TSHR-peptide tolerance trial in Graves', the CAR-T-for-autoimmunity reviews, and the novel-T3 and thyroid-organoid work.